ABSTRACT:
In this study, we examined the hematological parameters between sickle cell disease, sickle cell trait and control individuals. Haematological parameters were compare among SS, AS and AA groups. However, significant difference were observed for HbF ((p<0.000), Hb ((p<0.000) HCT ((p<0.000), MCV ((p<0.000), except for MCH (P=0.757). Haematological parameters were comparable among male and female in study groups. However, no significant difference were observed excluding in SS patient for MCH ((p<0.035), in AS patients for Hb (p< =0.009) and in control (AA) for Hb ((p<0.001) and HCT ((p<0.007). HbF levels were higher in SS (19.39±7.14) patients than AS (1.06±0.74) and control (0.12±0.1). Highly significant difference for HbF level ((p<0.000) was observed among these study groups. Furthermore, diverse ranges of HbF levels were also noted in present study.
Cite this article:
Sanjana Bhagat. Analysis of Haematological Parameters in Sickle Cell Trait and Sickle cell Disease patients of Chhattisgarh. Research Journal of Pharmacy and Technology. 2024; 17(7):3084-8. doi: 10.52711/0974-360X.2024.00483
Cite(Electronic):
Sanjana Bhagat. Analysis of Haematological Parameters in Sickle Cell Trait and Sickle cell Disease patients of Chhattisgarh. Research Journal of Pharmacy and Technology. 2024; 17(7):3084-8. doi: 10.52711/0974-360X.2024.00483 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2024-17-7-16
REFERENCES:
1. Steinberg MH. Predicting clinical severity in sickle cell anemia. British Journal of Haematology. 2005; May; 129(4): 465-81. doi: 10.1111/j.1365-2141.2005.05411.x
2. Adekile A. The genetic and clinical significance of fetal hemoglobin expression in Sickle Cell Disease. Medical Principles and Practice. 2021; June; 30(3): 201–11. doi: 10.1159/000511342
3. Silva DG, Belini Junior E, Carrocini GC, Torres Lde S, Ricci Junior O, Lobo CL, Bonini-Domingos CR, de Almeida EA. Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia. BMC Medical Genetics. 2013; Oct; 14: 108. doi: 10.1186/1471-2350-14-108
4. Stuart MJ, Nagel RL. Sickle cell disease. Lancet. 2004; Oct; 364 (9442): 1343-60. doi: 10.1016/S0140-6736(04)17192-4
5. Steinberg MH, Sebastani P. Genetic modifiers of sickle cell disease. American Journal of Hematology. 2012; Aug; 87(8): 795-03. doi: 10.1002/ajh.23232
6. Akinbami A, Dosunmu A, Adediran A, Oshinaike O, Adebola P, Arogundade O. Haematological values in homozygous sickle cell disease in steady state and haemoglobin phenotypes AA controls in Lagos, Nigeria. BMC Research Notes. 2012; Aug; 5: 396. doi: 10.1186/1756-0500-5-396
7. Brittenham GM, Schechter AN, Noguchi CT. Hemoglobin S polymerization primary determinant of the hemolytic and clinical severity of the sickling syndromes. Blood.1985; 65(1): 183–89.
8. Okpala I. The management of crises in sickle cell disease. European Journal of Haematology.1998; Jan; 60(1): 1-6. doi:10.1111/j.1600-0609.1998.tb00989.x
9. Donaldson A, Thomas P, Serjeant BE, Serjeant GR. Foetal haemoglobin in homozygous sickle cell disease: a study of patients with low HBF levels. Clinical and Laboratory Haematology. 2001; Jan; 23(5): 285–89. doi: 10.1046/j.1365-2257.2001.00412.x
10. Balgir RS. Phenotypic diversity of sickle cell disorder with special emphasis on public health genetics in India. Current Science. 2010; April; 98(8): 1096-02.
11. Keikhaei B, Galehdari H, Pedram M, Jaseb K, Bashirpour SH, Zandian KH, Samadi B. Beta-globin gene cluster haplotypes in Iranian sickle cell patients: relation to some hematologic parameters. Iranian Journal of Blood and Cancer. 2012; 4(3): 105-10.
12. da Silva MAL, Friedrisch JR, Bittar CM, Urnau M, Merzoni J, Valim VS, Amorin B, Pezzi A, Chies JAB, da Rocha Silla LM. β-globin gene cluster haplotypes and clinical severity in sickle cell anemia patients in Southern Brazil. Open Journal of Blood Disease. 2014; 4: 16-23. http://dx.doi.org/10.4236/ojbd.2014.42003
13. Rao SS, Goyal JP, Raghunath SV, Shah VB. Hematological profile of sickle cell disease from South Gujarat, India. Hematology Reports. 2012; May; 4(2): e8. doi: 10.4081/hr.2012.e8.
14. Kato GJ, Steinberg MH, Gladwin MT. Intravascular hemolysis and the pathophysiology of sickle cell disease. The Journal of Clinical Investigation. 2017; Mar 1; 127(3): 750-760. doi: 10.1172/JCI89741
15. Serjeant GR, Foster K, Serjeant BE. Red cell size and haematological features of homozygous sickle cell disease. British Journal of Haematology. 1981; Jul; 48(3): 445-49. doi: 10.1111/j.1365-2141.1981.tb02736.x
16. Omoti CE. Haematological values in sickle cell anaemia in steady state and during vaso-occlusive in Benin City, Nigeria. Annals of African Medicine. 2005; 4(2): 62-67.
17. Antwi-Boasiako C, Ekem I, Abdul-Rahman M, Sey F, Doku A, Dzudzor B. Dankwah GB, Out KH, Ahenkorah J, Aryee R. Hematological parameters in Ghanaian sickle cell disease patients. Journal of Blood Medicine. 2018; Oct; 31 (9): 203–09. doi:10.2147/JBM.S169872
18. Hove VL, Schisano T, Brace L. Anemia diagnosis, classification, and monitoring using cell-dyn technology reviewed for the new millennium. Laboratory Hematology. 2000; Jan; 6: 93-108.
19. Platt OS, Thorington BD, Brambilla DJ, Milner PF, Rosse EF, Vichinsky E, Kinney TR. Pain in sickle cell disease Rates and risk factors. The New England Journal of Medicine. 1991; 325(1): 11–16. doi:10.1056/NEJM199107043250103
20. Rana I Ahmad, Haider A. Al-Barry, Salwa I. Salloum. Fetal Hemoglobin (HbF) levels in Sickle cell anemia patients in Lattakia, Syria. Research Journal of Pharmacy and Technology. 2020; 13(7): 3246-3248.
21. Rahimi Z, Vaisi-Raygani A, Merat A, Haghshenass M, Rezaei M. Level of hemoglobin F and Gγ gne expression in sickle cell disease and their association with haplotype and XmnI polymorphic site in South of Iran. Iranian Journal of Medical Sciences. 2007; Dec; 32(4): 234-39.
22. Pandey S, Pandey S, Mishra RM, Saxena R. Modulating effect of the -158 Gγ (C→T) XmnI polymorphism in Indian sickle cell patients. Mediterranean Journal of Hematology and Infectious Disease. 2012; Jan; 4(1): e2012001. doi: 10.4084/MJHID.2012.001.
23. Akinsheye I, Alsultan A, Solovieff N, Ngo D, Baldwin CT, Sebastiani P, Chui DH, Steinberg MH. Fetal haemoglobin in sickle cell anemia. Blood. 2011; Jul; 118(1): 19-27. doi: 10.1182/blood-2011-03-325258.
24. Thein SL, Menzel S, Lathrop M, Garner C. Control of fetal hemoglobin: new insight emerging from genomics and clinical implications. Human Molecular Genetics. 2009; Oct; 18(R2): R216-23. doi: 10.1093/hmg/ddp401
25. Sebastiani P, Nolan VG, Baldwin CT, Abad-Grau MM, Wang L, Adewoye, AH, McMahon LC, Farrer LA, Taylor JG, Kato GJ, Gladwin MT, Steinberg MH. Predicting severity of sickle cell disease. Blood. 2007; Oct; 110(7): 2727-2735. doi: 10.1182/blood-2007-04-084921
26. Steinberg MH. Genetic Etiologies for Phenotypic Diversity in Sickle Cell Anemia. The Scientific World Journal. 2009; Jan; 9: 46-67. doi: 10.1100/tsw.2009.10.